Beneficial effects of rutin and L-arginine coadministration in a rat model of liver ischemia-reperfusion injury.

Acquaviva R, Lanteri R, Li Destri G, Caltabiano R, Vanella L, Lanzafame 8, Di Cataldo A, Li Volti G, Di Giacomo C. Beneficial effects of rutin and L-arginine coadministration in a rat model of liver ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 296: G664-G670, 2009. First published December 24, 2008; doi: 10.1152/ajpgi.90609.2008.-Reperfusion following liver ischemia results in oxidative stress leading to liver injury. The aim of this study was to investigate the combined effects of two antioxidant agents, rutin and L-arginine, in rat liver ischemia-reperfusion (I/R). Male Wistar rats were divided into five groups: 1) sham operated, 2) hR. 3) hR + rutin, 4) hR + L-arginine, and 5) YR + rutin + L-arginlne. Plasmatic and hepatic levels of alanine transaminase (ALT), aspartate transaminase (AST), lipid peroxides (LOOH), and thiol groups (RSH) were examined, as well as DNA fragmentation and liver histopathology. Furthermore, to elucidate the pathophysiological processes involved in the antioxidant mechanism(s) of rutin and L-arginine, we assessed the expression of inducible (iNOS) and endothelial nitric oxide synthase (eNOS) isoforms and heme oxygenase-1 (HO-1), both playing key roles in the biochemical cascade of liver injury. Significant increase in plasmatic ALT and AST activities were observed in untreated YR rats compared with sham-operated animals, whereas treatment with rutin or L-arginine in YR rats reduced hepatic damage. Interestingly, combined therapy with rutin and Larginine resulted in a further reduction of plasmatic ALT and AST activities compared with rutin or L-arginine alone. These results were further confirmed by the analysis of DNA fragmentation, LOOH, RSH groups, and liver histopathology, which showed the highest protective effects following the coadministration of rutin and Larginine. Finally, the combined therapy protocol resulted in a significant induction of liver HO-1 and a concomitant reduction of iNOS expression that may both be responsible for the beneficial effects of the proposed pharmacological protocol. [ABSTRACT FROM AUTHOR]